


Transcell's Transtoxbio & Wipro HOLMES™ Cooperation - Towards Human Relevant Science Based Next Gen Testing Platforms Disrupting Methodologies In Safety & Efficacy Validations

All medicines, cosmetics and vaccines as candidates carry potential risks as well as benefits throughout their life cycle from R&D till clinical presentation. An appropriate and relevant level of emendation on both the safety and efficacy of these products will facilitate the best use of regulatory and industry resources to control whole risks in the benefit of the patients or the user population. While there are established preclinical models and quality checking methods followed by Pharma and BioPharma global industry., there has been a hue and cry on developing, adopting next generation predictive human model systems as alternatives to animal models in R&D till production stages.

Transcell Oncologics developed Transtoxbio is a portfolio of all new human surrogate cell/tissue based progenitor in vitro systems yielding human specific readouts upon treatment with test samples. Built on their proprietary cell and tissue based platform technology, Transtoxbio offers and identifies itself as a support partner to Industry to perform human relevant R&D and develop medicines or cosmetics or vaccines tested on humanized models and meant for clinics.

Wipro HOLMES™, Wipro's Artificial Intelligence (AI) and automation platform, is the bridge between Foundational AI algorithm builders and Applied AI. HOLMES Platform focus on enabling key business challenges using Advanced AI.

Transcell and Wipro HOLMES™ intend to redefine and re-imagine certain in vitro safety and efficacy testing protocols by integrating their platforms through AI & cognitive computing-based elucidations and leveraging Stem Cell Technology for global Pharma/BioPharma industry specific in vitro testing requirements. The goal of this coming together initiative is to create better archetypes for understanding healthy human and patient context prioritizing pharma/biopharma candidates, improve predictivity; reduce time, money, and replace animals in biomedical developmental stages.



The aim of this gathering is to Accelerate Bio-Innovations to Marketplace while Transcell-Wipro team joint presentation is on: Leveraging Stem Cell Technology For Biopharma In vitro Testing – Neurovirulence of Vaccines

In one of their first joint interactions with targeted forum, Subhadra Dravida, Founder CEO of Transcell and Sreekumar Choyarmadathil, Chief Platform Architect of Wipro HOLMES™ are pitching at ChemTECH organized two day conference scheduled on 25th & 26th February, 2021, that brings together ‘Who’s who’ of the Biopharmaceuticals and innovator biologics industries for deliberations on Bio-Pharmaceuticals: A Next Big Opportunity.

Join us there on 25th Feb’2021.